We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+102.44%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$187M
AUM Growth
+$85.3M
Cap. Flow
+$31.5M
Cap. Flow %
16.85%
Top 10 Hldgs %
57.79%
Holding
64
New
29
Increased
5
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$13.7M
2
SION
Sionna Therapeutics
SION
+$6.85M
3
DVAX
Dynavax Technologies
DVAX
+$5.79M
4
DFTX
Definium Therapeutics
DFTX
+$5.26M
5
AXSM icon
Axsome Therapeutics
AXSM
+$5.23M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$7.99M
2
ETNB
89bio
ETNB
+$5.65M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$5.39M
4
BBIO icon
BridgeBio Pharma
BBIO
+$4.6M
5
SMMT icon
Summit Therapeutics
SMMT
+$4.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
26
Assembly Biosciences
ASMB
$531M
$2.22M 1.19%
+65,273
New +$2.1M
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.11B
$2.09M 1.12%
255,370
+166,024
+186% +$1.91M
TARA icon
28
Protara Therapeutics
TARA
$230M
$1.92M 1.03%
360,000
– –
TRVI icon
29
Trevi Therapeutics
TRVI
$2.71B
$1.86M 0.99%
+148,292
New +$1.71M
TYRA icon
30
Tyra Biosciences
TYRA
$1.91B
$1.54M 0.83%
+58,677
New +$1.08M
TVTX icon
31
Travere Therapeutics
TVTX
$5.27B
$1.45M 0.78%
38,022
-15,605
-29% -$507K
VRDN icon
32
Viridian Therapeutics
VRDN
$1.99B
$1.35M 0.72%
+43,230
New +$1.19M
RZLT icon
33
Rezolute
RZLT
$444M
$1.21M 0.65%
+513,765
New +$4.03M
DNTH icon
34
Dianthus Therapeutics
DNTH
$5.77B
$1.08M 0.58%
+26,249
New +$1.02M
SPRB
35
Spruce Biosciences
SPRB
$120M
$1.06M 0.57%
+12,137
New +$1.3M
AARD
36
Aardvark Therapeutics
AARD
$128M
$912K 0.49%
+69,496
New +$867K
GMAB icon
37
Genmab
GMAB
$17.6B
$898K 0.48%
+29,162
New +$909K
PALI icon
38
Palisade Bio
PALI
$342M
$863K 0.46%
+367,103
New +$706K
FULC icon
39
Fulcrum Therapeutics
FULC
$243M
$815K 0.44%
+72,060
New +$733K
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.88B
$730K 0.39%
+31,738
New +$1.04M
PTN
41
Palatin Technologies
PTN
$16.2M
$522K 0.28%
+33,971
New +$632K
IVA
42
Inventiva
IVA
$1.09B
$465K 0.25%
+100,000
New +$465K
IPSC icon
43
Century Therapeutics
IPSC
$406M
$461K 0.25%
462,963
– –
BMEA icon
44
Biomea Fusion
BMEA
$92.5M
$310K 0.17%
250,000
– –
ENTX icon
45
Entera Bio
ENTX
$97.6M
$33.3K 0.02%
+17,142
New +$40.2K
BBIO icon
46
BridgeBio Pharma
BBIO
$15.9B
– –
-88,658
Closed -$4.6M
CRBP icon
47
Corbus Pharmaceuticals
CRBP
$167M
– –
-57,644
Closed -$729K
ETNB
48
DELISTED
89bio
ETNB
– –
-384,652
Closed -$5.65M
NBP
49
NovaBridge Biosciences American Depositary Shares
NBP
$206M
– –
-139,886
Closed -$529K
INSM icon
50
Insmed
INSM
$23.5B
– –
-19,786
Closed -$2.85M
1
2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Superstring Capital Management held 64 positions worth $187M, up 84% from $102M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management deployed $31.5M of net new capital in Q4 2025, opening 29 new positions and adding to 5 existing holdings. Its largest new stake was Sionna Therapeutics: 180,593 shares worth $7.43M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $7.99M trimmed.

  • Superstring Capital Management's largest Q4 2025 buy was Sionna Therapeutics: 180,593 shares worth $7.43M.
  • Superstring Capital Management added most to UroGen Pharma in Q4 2025, an estimated $13.7M increase.
  • Superstring Capital Management's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $7.99M.
  • Superstring Capital Management fully exited 89bio in Q4 2025, selling an estimated $5.65M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $187M portfolio in Q4 2025.
  • Superstring Capital Management opened 29 new positions and closed 19 in Q4 2025.
  • Superstring Capital Management's portfolio value rose 84% quarter-over-quarter to $187M.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.